Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03866759
Other study ID # STIPnet Study
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 24, 2019
Est. completion date August 22, 2022

Study information

Verified date November 2022
Source University Hospital, Essen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The University Hospital Essen is sponsoring the Multicenter human immunodeficiency virus (HIV) and sexually transmitted infections Prevention Network Study (STIPnet) which is funded by Janssen, Pharmaceutical Companies of Johnson & Johnson. STIPnet study is a prospective observational cohort study aiming to determine the incidence and point prevalence of HIV infection and the most common sexually transmitted infections (STIs) in individuals with sexual risk behavior. In addition, the University Hospital Essen will examine whether individuals at risk for HIV and STI infections would retain in such a study (retention rate) and would be willing to participate in potential HIV and STI prevention trials (willingness to participate).


Description:

To develop and test novel prevention methods or interventions against sexually transmitted infections (STIs), knowledge is required on whether there are increased rates of transmission in a given population. In order for trials testing new prevention methods to be feasible and affordable, the goal is to define a group at risk where there will be at least an annual 3% incidence of new infections of the respective STI. The group definitions will be based on factors such as gender, age, sexual behavior, economic status and others. However, defining such groups is labor-intensive and costly and often not do-able for vaccine developers and developers of novel prevention/diagnostic methods. Thus, as identification and testing of the most at-risk groups to study these medicinal products is too costly, only a limited number of novel prevention methods are brought into clinical trials. Here the investigators plan to define factors such as behavioral or co-infections associated with individual STIs for potential future prevention trials. Given the increased susceptibility of human immunodeficiency (HIV) infection with STI infections, early diagnosis and treatment of STI is substantial to reduce risk factor of HIV acquisition and to inform individuals about their risk of becoming HIV infected. As STIs are a crucial factor in the scope of an incidence analysis of HIV in men who have sex with men (MSM) and are often underdiagnosed, extensive screening measures are implemented within this study. Thus, the STIPnet study is building up a platform for effective recruitment, retention and assess important epidemiological patterns and thus, designed as a vaccine preparedness study, to gather information on the most common STIs and prepare sites for potential future vaccine trials. Indeed, several potential HIV&STI vaccines are currently in development. At-risk volunteers are screened every three months for HIV and other STIs, thereby establishing disease prevalence and incidence in communities that might someday support future vaccine trials. Behavioural data are also collected and participants complete a questionnaire that assesses the willingness to participate in future vaccine studies.


Recruitment information / eligibility

Status Completed
Enrollment 3593
Est. completion date August 22, 2022
Est. primary completion date August 22, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. HIV-uninfected as defined as negative HIV-Ab-Elisa, negative HIV viral load or negative HIV Ag-Test at time point of screening. 2. 18-55 years of age 3. Male sex - (at birth, chosen or intersex) 4. Able and willing to give informed consent 5. Able to read and write in local or English language 6. Willing to show identification card 7. Willing to be followed for at least 12 months in the study and undergo study procedures including testing for HIV and receipt of HIV test results 8. Willing to provide contact information for themselves and, if available, one personal contact who would know their whereabouts during the study period 9. Willing to provide information regarding risk behaviors 10. Demonstrates any one of the following risk factors: 1. reports condomless anal intercourse with at least two unique male partners (unknown HIV status or HIV+ untreated individuals) in the past 24 weeks or 2. documented history (lab work, physician's note etc) of syphilis, rectal neisseria gonorrhea, mycoplasma genitalium, chlamydia or acute Hepatitis C virus (HCV) infection in the past 24 weeks Exclusion Criteria: 1. Any significant condition (including medical, psychologic/psychiatric and social) which, in the judgment of the study investigator, might interfere with the conduct of the study or be detrimental to the participant. 2. Prior or concurrent participation in a candidate HIV vaccine study, unless documented placebo recipient. 3. Concurrent participation in investigational HIV treatment or prevention studies (Please note: previous participation is not an exclusion criterion). 4. Employees of the study sites cannot participate but are eligible to participate at a different study site.

Study Design


Intervention

Behavioral:
Determine the Incidence and Point Prevalence
Determine the Incidence and Point Prevalence of human immunodeficiency virus (HIV) Infection and the Most Common Sexually Transmitted Infections in Individuals With Sexual Risk Behavior.

Locations

Country Name City State
France Centre Hospitalier Universitaire de Bordeaux Bordeaux
France Hôpital de la Croix-Rousse Lyon
France Hôpital Lariboisière Paris
France Hôpital Saint-Antoine Paris
France Hospital Saint Louis Paris
Hungary Semmelweis University Budapest
Italy Hospital Maggiore Policlinico Milan
Italy Hospital San Raffaele Milan
Italy National Institute for Infectious Diseases L. Spallanzani Rome
Poland Centrum PrEP Gdansk Gdansk
Poland Pomeranian Medical University Szczecin
Poland Chmielna Express Warsaw Warszawa
Poland Center for Prevention and Treatment of Infectious Diseases and Addiction Treatment Wroclaw
Spain Hospital Universitari Germans Trias i Pujol Barcelona
Spain Vall d'Hebron Research Institute Barcelona

Sponsors (2)

Lead Sponsor Collaborator
Hendrik Streeck Janssen, LP

Countries where clinical trial is conducted

France,  Hungary,  Italy,  Poland,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Choice of a cohort of volunteers at-risk for HIV and other STIs Participants will receive questionnaires. The group definitions will be based on factors such as gender, age, education, sexual behavior, economic status, pre- and post-exposure prophylaxis and others. Descriptive statistics will be generate to choose a cohort of volunteers at-risk for HIV and other STIs. Through study completion, an average of 2 years
Primary Relationship between STIs and certain behavior and risk of HIV infection Participants will receive a questionnaire about behavior and risk of HIV infection. Descriptive statistics will be generate to summarize the relationship between STIs and HIV infection. Through study completion, an average of 2 years
Primary Incidence of HIV and other STIs in a cohort of individuals at risk for HIV and other STI infections Descriptive statistics will be generated to summarize incidence (as measured as new HIV and STI infections occurring during the study period) HIV and STI infections. The power calculation targets a 3% incidence rate per year. Through study completion, an average of 2 years
Secondary Prevalence of HIV and other STIs in a cohort of individuals at risk for HIV and other STI infections Descriptive statistics will be generated to summarize prevalence (as measured as HIV and STIs positive cases during screening visit) HIV and STI infections. Baseline HIV and STI prevalence will be defined as the number of HIV or STI infected individuals identified at screening divided by the total number of individuals who are screened for HIV or STI.
Once enrollment is completed, baseline HIV or STI prevalence will be calculated.
At screening (until last participant is included), an average of 1 year
Secondary Co-occurence of STIs and HIV Analysis of laboratory and other testing results. Descriptive statistics will be generated to evaluate co-occurence of STIs and HIV. Through study completion, an average of 2 years
Secondary Retention rates for prospective prevention studies for individuals at risk for HIV and STI infections. The primary assessment of retention will be conducted assuming a binomial distribution and individuals will be considered retained at 12 months if they complete the final study visit. Retention will also be estimated with 95% CI for each study visit. A summary of participant attendance and loss to follow-up will be made every 3 months to monitor the retention rate by site, and to help ensure that the overall 12-month retention rate of the study visit will be no less than 85%. Through study completion, an average of 2 years
Secondary Willingness to participate in future clinical trials, such as those of candidate vaccines through questionnaire Willingness to participate in vaccine trials will be estimated assuming a binomial distribution. Factors associated with willingness to participate in vaccine trial will be evaluated using logistic regression models At enrollment (day 0, can be same day as screening day) and at visit 4 (visit 4 is day 364)
Secondary Attitudes regarding HIV and STI prevention methods Attitudes regarding PrEP will be evaluated using descriptive statistics and questionnaires. Behavioral questionnaire over time will be assessed by frequency tables and bar graphs. At screening, at visit 1, 2, 3, 4 (visit 1 is day 84, visit 2 is day 168, visit 3 is day 252 and visit 4 is day 364)
Secondary Incidence between individuals at risk for HIV and STI infections across sites and countries Descriptive statistics will be generated to summarize incidence (as measured as new HIV and sexual transmitted infections occurring during the study period) HIV and STI infections. Data may be compared across sites for comparison and evaluation of factors impacting incidence. Through study completion, an average of 2 years
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2

External Links